C12Q 2600/112
Disease subtyping, staging or classification
C12Q2600/112 (Disease subtyping, staging or classification) appears on 2,200 US grants and 4,869 published applications in this corpus.
Search patents in C12Q- Granted patents
- 2,200
- Published applications
- 4,869
- Assignees
- 1,874
- Inventors
- 8,622
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 1 | 0 |
| 1993 | 5 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 11 | 0 |
| 1997 | 22 | 0 |
| 1998 | 24 | 0 |
| 1999 | 30 | 0 |
| 2000 | 20 | 0 |
| 2001 | 36 | 4 |
| 2002 | 22 | 28 |
| 2003 | 18 | 52 |
| 2004 | 20 | 77 |
| 2005 | 19 | 100 |
| 2006 | 22 | 133 |
| 2007 | 25 | 140 |
| 2008 | 42 | 103 |
| 2009 | 52 | 176 |
| 2010 | 72 | 214 |
| 2011 | 78 | 270 |
| 2012 | 71 | 237 |
| 2013 | 66 | 209 |
| 2014 | 95 | 227 |
| 2015 | 106 | 299 |
| 2016 | 105 | 315 |
| 2017 | 124 | 220 |
| 2018 | 125 | 223 |
| 2019 | 147 | 311 |
| 2020 | 136 | 250 |
| 2021 | 168 | 243 |
| 2022 | 129 | 293 |
| 2023 | 117 | 201 |
| 2024 | 114 | 209 |
| 2025 | 107 | 171 |
| 2026 | 56 | 164 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biomarkers of renal osteodystrophy type6 Oct 2026US 12,753,440 B2The Trustees of Columbia University in the City of New York
- Molecular profiling of tumors6 Oct 2026US 12,754,193 B2Caris MPI, Inc.
- Compositions and methods for cancer diagnosis and prognosis29 Sep 2026US 12,747,478 B2King Abdullah University of Science and Technology
- Methods of identifying subjects having an increased risk of developing a coronavirus infection and treatment thereof15 Sep 2026US 12,735,752 B2Regeneron Pharmaceuticals, Inc.
- Unsupervised machine learning methods for classifying a lupus disease state of a subject25 Aug 2026US 12,718,954 B2Ampel, LLC
- Methods for cancer detection and monitoring8 Oct 2026US 2026/0308683 A1Natera, Inc.
- Genomic alterations in the tumor and circulation of pancreatic cancer patients8 Oct 2026US 2026/0308686 A1The Johns Hopkins University
- Epigenetic Signature of T Cell Aging and Malignancy8 Oct 2026US 2026/0308690 A1Regents of the University of Minnesota
- A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer1 Oct 2026US 2026/0297088 A1Antares Therapeutics, Inc.
- Certification of animal-derived product(s) based on dna-methylation1 Oct 2026US 2026/0297647 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Most cited
By later US patents
- Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase525US 5,272,057 AGeorgetown University · 1993
- Partitioning and processing of analytes and other species361US 9,644,204 B210x Genomics, Inc. · 2017
- Polynucleotide barcode generation238US 9,388,465 B210x Genomics, Inc. · 2016
- Determination of status in neoplastic disease237US 4,968,603 AThe Regents of the University of California · 1990
- Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays234US 7,410,764 B2The Penn State Research Foundation · 2008